| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 1580 | 2017 |
| Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma R Motzer, B Alekseev, SY Rha, C Porta, M Eto, T Powles, V Grünwald, ... New England Journal of Medicine 384 (14), 1289-1300, 2021 | 1198 | 2021 |
| Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma TK Choueiri, T Powles, M Burotto, B Escudier, MT Bourlon, B Zurawski, ... New England Journal of Medicine 384 (9), 829-841, 2021 | 1195 | 2021 |
| [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... The Lancet 397 (10276), 797-804, 2021 | 607 | 2021 |
| Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study ES Antonarakis, JM Piulats, M Gross-Goupil, J Goh, K Ojamaa, ... Journal of Clinical Oncology 38 (5), 395, 2020 | 540 | 2020 |
| Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial J Pfisterer, CM Shannon, K Baumann, J Rau, P Harter, F Joly, J Sehouli, ... The Lancet Oncology 21 (5), 699-709, 2020 | 136 | 2020 |
| KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). JS De Bono, JCH Goh, K Ojamaa, JM Piulats Rodriguez, CG Drake, ... Journal of Clinical Oncology 36 (15_suppl), 5007-5007, 2018 | 114 | 2018 |
| Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled … JA Ledermann, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet Oncology 21 (5), 710-722, 2020 | 100 | 2020 |
| PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP … JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, ... The Lancet Oncology 23 (11), 1389-1397, 2022 | 92 | 2022 |
| TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC … MS Hofman, L Emmett, SK Sandhu, A Iravani, AM Joshua, JC Goh, ... Journal of Clinical Oncology 38 (15_suppl), 5500-5500, 2020 | 78 | 2020 |
| Nivolumab+ cabozantinib (NIVO+ CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended … RJ Motzer, TK Choueiri, T Powles, M Burotto, MT Bourlon, JJ Hsieh, ... Journal of Clinical Oncology 39 (6_suppl), 308-308, 2021 | 74 | 2021 |
| Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial RJ Motzer, P Russo, V Grünwald, Y Tomita, B Zurawski, O Parikh, S Buti, ... The Lancet 401 (10379), 821-832, 2023 | 65 | 2023 |
| PARAGON: a phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors M Tang, RL O'Connell, F Amant, P Beale, O McNally, KM Sjoquist, P Grant, ... Gynecologic Oncology 154 (3), 531-538, 2019 | 60 | 2019 |
| Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures K Pittman, YC Antill, A Goldrick, J Goh, RH De Boer Asia‐Pacific Journal of Clinical Oncology 13 (4), 266-276, 2017 | 59 | 2017 |
| TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic … MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... Lancet 397 (10276), 797-804, 2021 | 57 | 2021 |
| TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival … MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... Journal of Clinical Oncology 40 (16_suppl), 5000-5000, 2022 | 55 | 2022 |
| LBA4 Adjuvant nivolumab plus ipilimumab (NIVO+ IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the … RJ Motzer, P Russo, V Gruenwald, Y Tomita, B Zurawski, OA Parikh, ... Annals of Oncology 33, S1430, 2022 | 54 | 2022 |
| Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised placebo‐controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer I Ray‐Coquard, D Cibula, MR Mirza, A Reuss, C Ricci, N Colombo, ... International journal of cancer 146 (2), 439-448, 2020 | 47 | 2020 |
| Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial–ANZGOG 0903 L Mileshkin, R Edmondson, RL O'Connell, KM Sjoquist, J Andrews, ... Gynecologic Oncology 154 (1), 29-37, 2019 | 47 | 2019 |
| Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial HJ Gray, B Benigno, J Berek, J Chang, J Mason, L Mileshkin, P Mitchell, ... Journal for immunotherapy of cancer 4, 1-10, 2016 | 47 | 2016 |
Linda MileshkinPeter MacCallum Cancer CentreVerified email at petermac.org
